From CNBC:

Novo Nordisk’s Ozempic, a popular injectable antidiabetic drug, reduced the risk of kidney disease progression by 24% in diabetic patients with chronic kidney disease compared to a placebo. The positive late-stage trial results also showed benefits beyond weight loss, leading to plans for expanded approval in the U.S. and Europe.

The trial, called FLOW, ended a year early due to the favorable outcomes in 3,500 patients with diabetes and chronic kidney disease. Novo Nordisk faces competition from Eli Lilly, but shows promising results for Ozempic and its weight loss injection, Wegovy, in improving overall health outcomes for patients.

Ozempic’s potential in treating chronic kidney disease, which affects 40% of people with diabetes, could lead to significant new treatment opportunities. The drug’s broader health benefits and positive trial results could pave the way for expanded insurance coverage and increased market share in the competitive pharmaceutical landscape.



Read more at CNBC: Novo Nordisk’s Ozempic cuts risk of kidney disease progression